title: Alvimopan.
abstract: Alvimopan, a trans-3,4-dimethyl-4-(3-hydroxy-phenyl) piperidine, is a selective, peripherally acting micro-opioid receptor antagonist that is available for short-term use in hospitalized patients who have undergone bowel resection. The efficacy of alvimopan in the management of postoperative ileus has been evaluated in five phase III trials; four conducted in North America and one conducted in Europe/Australasia. Patients who had undergone partial large or small bowel resection surgery with primary anastomosis were randomized to receive alvimopan 12 mg or placebo as a single oral pre-operative dose followed by twice-daily administration for up to 7 days postoperatively. In the five phase III trials, alvimopan was significantly more effective than placebo in reducing the time to recovery of upper and lower gastrointestinal (GI) function, as assessed using a two-component endpoint (GI2) comprising time to tolerance of solid food and first bowel movement. The mean time to reach the GI2 endpoint was 11-26 hours sooner with alvimopan than with placebo. In the phase III trials conducted in North America, the time to writing the hospital discharge order was 13-21 hours sooner with alvimopan than with placebo. Alvimopan did not reduce opioid-induced analgesia and/or increase the amount of opioids administered postoperatively. Short-term alvimopan was generally well tolerated in adults undergoing bowel resection.
authors.affiliation: Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Monique P
authors.initials: MP
authors.lastname: Curran
authors.forename: Gayle W
authors.initials: GW
authors.lastname: Robins
authors.forename: Gayle W
authors.initials: GW
authors.lastname: Robyns
authors.forename: Lesley J
authors.initials: LJ
authors.lastname: Scott
authors.forename: Caroline M
authors.initials: CM
authors.lastname: Perry
mesh_terms: D000701:Analgesics, Opioid / Q000009:adverse effects; D000818:Animals; D013505:Digestive System Surgical Procedures; D005765:Gastrointestinal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D005769:Gastrointestinal Motility / Q000187:drug effects; D006207:Half-Life; D006801:Humans; D010149:Postoperative Pain / Q000150:complications / Q000188:drug therapy; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors*
chemical_list: D000701:Analgesics, Opioid; D005765:Gastrointestinal Agents; D010880:Piperidines; D017450:Receptors, Opioid, mu; C419502:alvimopan
references.citation: Surg Endosc. 2006 Jan;20(1):64-70
references.pmid: 16333556
references.citation: Clin Pharmacol Ther. 2008 May;83(5):770-6
references.pmid: 17653140
references.citation: Surgery. 2007 Oct;142(4):478-86
references.pmid: 17950339
references.citation: Dis Colon Rectum. 2004 Apr;47(4):516-26
references.pmid: 14978625
references.citation: Aliment Pharmacol Ther. 2008 Aug 1;28(3):312-25
references.pmid: 19086236
references.citation: Ann Surg. 2004 Oct;240(4):728-34; discussion 734-5
references.pmid: 15383800
references.citation: J Med Chem. 1994 Jul 22;37(15):2262-5
references.pmid: 8057274
references.citation: Clin Gastroenterol Hepatol. 2003 Mar;1(2):71-80
references.pmid: 15017498
references.citation: Clin Pharmacol Ther. 2001 Jan;69(1):66-71
references.pmid: 11180040
references.citation: Clin Gastroenterol Hepatol. 2005 Aug;3(8):784-91
references.pmid: 16234007
references.citation: Am J Surg. 2001 Nov;182(5A Suppl):27S-38S
references.pmid: 11755894
references.citation: Dis Colon Rectum. 2005 Jun;48(6):1114-25; discussion 1125-6; author reply 1127-9
references.pmid: 15906123
references.citation: Arch Surg. 2003 Feb;138(2):206-14
references.pmid: 12578422
references.citation: J Am Coll Surg. 2007 Apr;204(4):609-16
references.pmid: 17382220
references.citation: Drugs. 2002;62(18):2603-15
references.pmid: 12466000
references.citation: Am J Surg. 2001 Nov;182(5A Suppl):3S-10S
references.pmid: 11755891
references.citation: Pharmacol Ther. 2008 Jan;117(1):162-87
references.pmid: 18022696